Welcome to our dedicated page for Jazz Pharmaceuticals Plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jazz Pharmaceuticals plc filings are most useful for verifying how its neuroscience and oncology portfolio translates into reported results, guidance and operating expense trends. The company’s 8-K filings around earnings break out product sales for Xywav, Xyrem, Epidiolex/Epidyolex, Rylaze/Enrylaze, Zepzelca, Defitelio/defibrotide, Modeyso, Vyxeos and Ziihera, while also discussing R&D, SG&A, cash flow, debt and non-GAAP reconciliations.
Other 8-K disclosures document HERIZON-GEA-01 trial results, the Avadel settlement, director and officer changes, and annual general meeting vote results. For JAZZ, the most decision-useful disclosure areas are regulatory events for zanidatamab, commercial uptake of approved medicines, litigation outcomes and governance changes.
Jazz Pharmaceuticals plc director Bruce C. Cozadd reported an open-market sale of 6,000 Ordinary Shares of Jazz Pharmaceuticals on May 1, 2026, at $203.33 per share. After this transaction, he directly holds 378,682 Ordinary Shares.
According to the filing, this sale was executed automatically under a pre-arranged trading plan adopted on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, meaning the timing did not involve a discretionary decision by Cozadd.
Jazz Pharmaceuticals reported sharply improved results for the quarter ended March 31, 2026. Total revenues rose to $1,068.9 million from $897.8 million, driven by higher product sales across sleep, epilepsy and oncology franchises.
Net income reached $293.1 million, compared with a net loss of $92.5 million a year earlier, helped by a $122.8 million gain on the sale of a rare pediatric disease priority review voucher and lower selling, general and administrative expenses. Cash and cash equivalents increased to $1,844.3 million, while total debt remained around $5.35 billion, leaving the company with significant liquidity to support its rare disease portfolio and R&D pipeline.
Jazz Pharmaceuticals reported strong first-quarter 2026 results, with total revenues of $1.07 billion, up 19% year over year, and GAAP diluted EPS of $4.43 versus a loss a year ago. Non-GAAP adjusted EPS was $6.34, and cash from operations reached $408 million.
Growth was driven by key products, including Xywav (up 18% to $408 million), Epidiolex/Epidyolex (up 15% to $249.8 million) and Zepzelca (up 60% to $101 million), plus initial Modeyso sales. The company ended March 31, 2026 with $2.9 billion in cash, cash equivalents and investments and $5.4 billion in long-term debt principal.
Jazz completed the sale of a Rare Pediatric Disease Priority Review Voucher for gross proceeds of $200 million (50% to Jazz), and reaffirmed its full-year 2026 total revenue guidance of $4.25–$4.5 billion along with both GAAP and non-GAAP margin and expense outlook.
Jazz Pharmaceuticals (Rule 144 notice): The filing reports sales of restricted common stock in lots of 6,000 shares. Two sale entries are shown with trade dates 03/03/2026 and 04/01/2026, each for 6,000 shares, with numeric amounts listed alongside those rows.
Jazz Pharmaceuticals PLC ownership filing shows Vanguard Capital Management reports beneficial ownership of 3,103,522 shares of common stock, representing 5.04% of the class. The filing lists sole voting power for 455,189 shares and sole dispositive power over 3,103,522 shares. The signature date on the filing is 04/30/2026.
Jazz Pharmaceuticals plc filed an Amendment No. 1 to its 2025 annual report to add Part III information normally drawn from its proxy, update the cover page and exhibit list, and provide new CEO/CFO certifications. The company reported an aggregate market value of non‑affiliate equity of about $6.25 billion as of June 30, 2025, and 62,738,815 ordinary shares outstanding as of April 15, 2026.
Jazz highlights record 2025 performance with strong product sales, including Xywav $1,657.0 million and Epidiolex/Epidyolex $1,059.2 million, plus oncology contributions from Zepzelca, Rylaze/Enrylaze, Modeyso and Ziihera. The board describes a pay‑for‑performance design: 2025 bonuses funded at 150% of target based on corporate goals, while 2023–2025 PSUs paid at 94% of target after operational scoring and relative TSR adjustments.
The amendment details a staggered board, refreshed committee memberships and extensive biopharma, financial and governance experience among directors and executives. It also outlines executive incentives tied to multi‑year commercial, pipeline and capital deployment objectives, supported by stock ownership guidelines, a clawback policy, insider‑trading controls and change‑in‑control and severance plans.
Jazz Pharmaceuticals plc director Bruce C. Cozadd sold 6,000 ordinary shares of the company in open-market transactions. The sales occurred on 2026-04-01 at weighted average prices of $190.2220, $190.9383 and $191.7447 per share. According to a footnote, these trades were executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025, meaning the timing was not discretionary. After the transactions, Cozadd directly owned 384,682 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals proposed sale notice (Form 144): A notice lists a proposed sale of 6,000 shares of Common Stock with a transaction date shown as 04/01/2026 and Nasdaq as the market. The filing also records a prior sale of 6,000 shares on 03/03/2026 for $1,118,613.32.
Jazz Pharmaceuticals PLC: The Vanguard Group files an amended Schedule 13G/A reporting 0 shares beneficially owned and 0% of the common stock.
The amendment states that on January 12, 2026 The Vanguard Group, Inc. completed an internal realignment and certain subsidiaries will now report holdings separately in reliance on SEC Release No. 34-39538.
Jazz Pharmaceuticals director Bruce C. Cozadd reported a tax-related share disposition. On the vesting of previously granted restricted stock units, 15,114 Ordinary Shares were withheld at $188.69 per share to satisfy tax obligations, reducing his directly held stake to 390,682 Ordinary Shares. This Form 4 reflects a tax-withholding transaction rather than an open-market trade.